Patent ID: 11939637
Assignee: THE GENERAL HOSPITAL CORPORATION
Field: Measurement (Instruments)
Classification: CPC C  G | IPC C  G

Claim 1:
2. The method according to claim 1, further comprising:
(a) detecting a genetic alteration in the tumor, wherein the genetic alteration is a mutation in a gene selected from the group consisting of CASP8, B2M, PIK3CA, SMC1A, ARID5B, TET2, ALPK2, COL5A1, TP53, DNER, NCOR1, MORC4, CIC, IRF6, MYOCD, ANKLE1, CNKSR1, NF1, SOS1, ARID2, CUL4B, DDX3X, FUBP1, TCP11L2, HLA-A, B or C, CSNK2A1, MET, ASXL1, PD-L1, PD-L2, IDO1, IDO2, ALOX12B and ALOX15B, or copy number gain, excluding whole-chromosome events, impacting any of the following chromosomal bands: 6q16.1-q21, 6q22.31-q24.1, 6q25.1-q26, 7p11.2-q11.1, 8p23.1, 8p11.23-p11.21, 9p24.2-p23, 10p15.3, 10p15.1-p13, 11p14.1, 12p13.32-p13.2, 17p13.1 and 22q11.1-q11.21; and
(b) administering an agent that stimulates the patient's preexisting immune response if a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.